The Centre for Process Innovation (CPI) has announced the launch of the new Medicines Manufacturing Innovation Centre (MMIC).

The centre will develop highly efficient technologies and enable industry, academia, healthcare providers and regulators to work together, as well as aiming to be a world leader in innovative small molecule medicines manufacturing.

Allowing users to test processes using advanced manufacturing technologies and ensuring that new medicines can reach patients effectively and efficiently, the MMIC will ultimately expand the country’s healthcare capabilities.

Located in Renfrewshire in Scotland, MMIC is a joint venture led by the Centre for Process Innovation (CPI) in partnership with the University of Strathclyde, the Medicines Manufacturing Industry Partnership, AstraZeneca and GSK. It is a £56 million investment, which includes £13 million from UK Research and Innovation through the Industrial Strategy Challenge Fund plus a further £15 million from Scottish Enterprise, as well as £7 million each from AstraZeneca and GSK.

Find out more here.

Share this article